article thumbnail

Biosimilar competition saves US healthcare $21 billion

European Pharmaceutical Review

Amgen’s 2022 market report has detailed how competition has driven savings across healthcare, estimating that a considerable number of biologics will be in competition with biosimilars in five to 10 years. More interchangeable biosimilars are estimated to be approved and launched in the US in the next few years.

article thumbnail

Is the launch environment really more competitive now?

pharmaphorum

It’s often stated – mostly without reference to data – that the environment for innovative launches is more competitive now than it ever has been. A second, “transitional era” from 2000-2015 was one of older specialty products, including those in multiple sclerosis, early immunological biologics, and oncologics.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Harnessing the Power of Generational Diversity as a Competitive Advantage

PM360

Today’s workforce includes Traditionalists (born 1927-1945), Boomers (1946-1964), Gen X (1965-1980), Millennials (1981-1996), and Gen Z (1997-2015). We have in front of us a unique opportunity to not only appreciate but harness the power of generational diversity as a competitive advantage.

article thumbnail

Pharma is big business whose goal is to maximize shareholder value

World of DTC Marketing

Many drug companies spent a significant portion of their R&D budget on finding ways to suppress generic and biosimilar competition while continuing to raise prices, rather than on innovative research. In a 2015 study of 36 cancer drugs that had recently been approved, only 5 showed extended life. Big pharma is big business.

Pharma 292
article thumbnail

Chinese manufacturers’ transition to innovative pharma requires more investment

Pharmaceutical Technology

China will continue to take steps towards becoming as competitive in high-value innovative pharma as it is in the generics industry, with The Wall Street Journal reporting Chinese biotechs raised $1.6tn through 568 venture financings last year, up from $11bn in 418 deals in 2020.

article thumbnail

Navigating the rapidly changing oncology treatment landscape: how digital tools can help

Impetus Digital

Increased competition and evolving standard of care New competitors are entering the market at a rapid pace, and competition is intensifying. This competitive intensity tends to focus on smaller patient populations with multiple treatment options (1,2). However, with rapid growth comes growing pains.

article thumbnail

470% price increases

World of DTC Marketing

AbbVie’s internal documents show that from 2015 to 2018, senior executive bonuses were tied directly to Humira’s net revenue, allowing them to profit from AbbVie’s price increases. AbbVie has obtained or applied for over 250 patents on Humira to block competition from lower-priced biosimilars.